Compounds > plerixafor
Page last updated: 2024-08-24

plerixafor and Autoimmune Diabetes

plerixafor has been researched along with Autoimmune Diabetes in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Huang, J; Li, T; Li, Y; Lu, H; Sui, M; Wang, S; Zeng, L; Zhang, P1
Albiero, M; Avogaro, A; Cappellari, R; Danna, M; DiPersio, J; Fadini, GP; Fiala, M; Menegazzo, L; Park, S; Poncina, N; Stockerl-Goldstein, K1
Drucker, DJ; Fujishima, H; Fujita, H; Morii, T; Narita, T; Sato, T; Seino, Y; Shimizu, T; Takahashi, T; Takashima, S; Tsukiyama, K; Yamada, Y1
Chen, J; Leng, Q; Nie, Y; Zou, Y1
Aboumrad, E; Madec, AM; Thivolet, C1

Other Studies

5 other study(ies) available for plerixafor and Autoimmune Diabetes

ArticleYear
SOCS3 inhibits the mesenchymal stromal cell secretory factor SDF-1-mediated improvement of islet function in non-obese diabetic mice.
    Stem cell research & therapy, 2023, 07-03, Volume: 14, Issue:1

    Topics: Animals; Blood Glucose; Chemokine CXCL12; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Graft Survival; Ligands; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Receptors, G-Protein-Coupled; Suppressor of Cytokine Signaling 3 Protein

2023
Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor.
    Diabetes, 2015, Volume: 64, Issue:8

    Topics: Adult; Benzylamines; Cyclams; Diabetes Mellitus, Type 1; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Male; Middle Aged; Prospective Studies; Receptors, CXCR4; Retrospective Studies

2015
Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
    Kidney international, 2016, Volume: 90, Issue:4

    Topics: Albuminuria; Animals; Benzylamines; Chemokine CXCL12; Cyclams; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Female; Fibrosis; Glomerular Filtration Rate; Glucagon-Like Peptide-1 Receptor; Heterocyclic Compounds; Humans; Hypoglycemic Agents; Kidney; Linagliptin; Liraglutide; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Receptors, CXCR4; Up-Regulation

2016
Elevated CXCL12 expression in the bone marrow of NOD mice is associated with altered T cell and stem cell trafficking and diabetes development.
    BMC immunology, 2008, Sep-15, Volume: 9

    Topics: Animals; Benzylamines; Bone Marrow; CD4-Positive T-Lymphocytes; Cell Movement; Chemokine CXCL12; Cyclams; Diabetes Mellitus, Type 1; Female; Gene Expression Regulation; Hematopoietic Stem Cells; Heterocyclic Compounds; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred NOD; Receptors, CXCR4

2008
The CXCR4/CXCL12 (SDF-1) signalling pathway protects non-obese diabetic mouse from autoimmune diabetes.
    Clinical and experimental immunology, 2007, Volume: 148, Issue:3

    Topics: Adoptive Transfer; Animals; Autoimmune Diseases; Benzylamines; Cells, Cultured; Chemokine CXCL12; Chemokines, CXC; Cyclams; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Female; Heterocyclic Compounds; Islets of Langerhans; Lymph Nodes; Male; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Receptors, CXCR4; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Th2 Cells

2007